Clinical trial
Prevention of GBS Colonization Via Immunity
NCT00128219 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00128219 |
|---|---|
| Title | Prevention of GBS Colonization Via Immunity |
| Official title | A Phase II Randomized, Double-Blinded, Comparative Clinical Trial for a Group B Streptococcus Serotype III-Tetanus Toxoid (GBS III-TT) Vaccine to Prevent Vaginal Acquisition of GBS Type III |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Beta Haemolytic Streptococcal Infection |
| Intervention type | Biological |
| Interventions | GBS III-TT, Tetanus and diptheria toxoids vaccine |
| Enrollment | 667 |
| Start date | Jul 1, 2003 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Aug 9, 2005 |
| Last update posted | Jan 27, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: